Skip to main content

Table 1 The criteria for improvements in facial angiofibroma lesions from baseline

From: Improved health-related quality of life in patients treated with topical sirolimus for facial angiofibroma associated with tuberous sclerosis complex

ImprovedReduced in ≥50% of lesionsImproved by ≥2 reddishness levels in ≥50% of lesions
UnchangedNot obviously changedNot obviously changed
AggravatedIncreased or newly formed papules in ≥50% of lesionsAggravated by ≥2 reddishness levels in ≥50% of lesions